A retrospective and prospective study of leiomyosarcoma systemic therapy outcomes informed by tumor genomics

Active Grant Awarded

Award ID
R01FD008219
Recipient
Awarding agency
Obligated
$345,343

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 4% complete
Funding agency
Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
Place of performance
New York, NY 10065, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration awarded Sloan-Kettering Institute For Cancer Research $345,343 on September 23, 2026, under CFDA 93.103, Food and Drug Administration Research. Grant R01FD008219 funds a retrospective and prospective study of leiomyosarcoma systemic therapy outcomes informed by tumor genomics. The recipient will link next-generation cancer sequencing results to the systemic therapies patients received for metastatic disease at its cancer centers. The work draws on sequencing data from over 400 patients and expects to sequence approximately 150 new patients a year across two sites. The study will develop a prospective database starting with patients already treated and will build risk stratification tools that the recipient will make publicly available. The stated ultimate goal is a clinical trial comparing physician choice with tool-selected treatment.

Place of performance is New York, NY 10065, and the period of performance ends August 31, 2030. The Office of Medical Products and Tobacco is the agency's listed alternate name.

Description

Abstract
The treatment of cancer is changing with the increasingly detailed understanding of cancer genomics. For patients with sarcoma, our understanding lags behind more common cancers, both from the rarity (< 1 % of all cancers in humans) and heterogeneity of sarcomas. This heterogeneity is manifested by 70 or so histologic subtypes, many with translocations, for which there are over 400 recognized. We seek to understand one of the most common forms of sarcoma better, specifically leiomyosarcoma (LMS). Between 2500-3000 people will get leiomyosarcoma arising in different parts of the body this year (uterus, branches of major veins, soft tissue as three common primary sites). Patients with leiomyosarcoma also represent the top accruing diagnosis for metastatic sarcomas in clinical trials due to frequent occurrence of lung and other metastases, which makes leiomyosarcoma the most common fatal form of sarcoma. While we have a general understanding of which drugs are active in this diagnosis, we do not understand how the molecular genetics of leiomyosarcoma affect response or resistance to systemic therapy. We will link what we know from our next-generation cancer sequencing results to the systemic therapies we have given to patients for metastatic disease at our cancer centers. We presently have access to over 400 patients' sequencing data, and we expect to sequence approximately 150 new patients a year between two sites. We will compare this information to the systemic therapy those patients have received, as we develop a prospective database starting with the patients we have already treated. In doing this, we will develop tools to aid in risk stratification that we will make available publicly. The ultimate goal of our work is a clinical trial to compare physician choice VS tool-selected treatment. This work will lay the foundation for such a clinical trial.

Quick answers

Who received award R01FD008219?

R01FD008219 was awarded to Sloan-Kettering Institute For Cancer Research by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award R01FD008219 worth?

$345,343 has been obligated on R01FD008219.

Which agency awarded R01FD008219?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008219, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award